IBD MarketSurge Growth 250 names Elbit Systems and Kinross Gold stock, as well as TG Therapeutics, stood out among today's IBD Screen Of The Day picks.
The IBD Stock Screener identified a whopping 183 names in the Rising Profit Estimates screen where analysts recently raised their earnings estimates. Two of these names sit in the top 10 groups of the 197 industry groups that Investor's Business Daily tracks. Both stocks have gained around 70% so far this year.
Kinross Gold Stock Dances Around A Buy Point
Kinross Gold stock is holding support at its 10-week moving average after a breakout in late June failed to progress. The gold stock gave back gains from the 15.96 buy point of a consolidation pattern and has been trading around the entry point.
Shares have climbed around 69% so far this year as part of their steep climb since March 2024. Gold stocks have risen along with the price of gold. Some analysts see the yellow metal reaching $4,000 in 2026, which could further boost the stock.
The gold miner reports its second-quarter results Wednesday, after the market close. Earnings are expected to pop 141%, following its tripled profit in the prior quarter.
Analysts recently raised their full-year 2025 earnings estimates to $1.35 per share, or nearly double the 68 cents per share in 2024. Profit is expected to climb another 15% in 2026.
FactSet estimates call for third-quarter sales growth to slow to 23% from 38%, with further deterioration over the following three quarters. The gold stock holds a top-notch 99 IBD Composite Rating.
Toronto-based Kinross has gold mines and projects in the U.S., Canada, Brazil, Chile, and Mauritania.
Kinross Gold is tied for the top spot out of 80 stocks in the Mining-Gold/Silver/Gems group. The group ranks 7th out of the 197 industry groups that Investor's Business Daily tracks.
Defense Name Elbit Systems Lands Big Contract
The Israel-based global defense company makes technology for products and systems used to protect air, space, land, and water. Its tech is used in drones, air defense systems, warfare, cybersecurity solutions, and by Homeland Security. Elbit is in the Aerospace/Defense group, which ranks No. 5 of the 197 IBD groups.
On Monday, Elbit Systems said the German Air Force awarded it a $260 million contract. The contract covers self-protection systems used to defend aircraft against infrared-guided missile threats.
Elbit Systems is in a newly formed flat base with a 476.04 buy point, which is also its all-time high. Shares have gained 75% year-to-date.
Its second-quarter profit jumped 42%, while its revenue growth accelerated to 22% from 12% four quarters ago.
Full-year 2025 earnings forecasts now expect $10.39 per share, or 19% growth, then a 30% boost to $13.55 in 2026.
The company has been a steady profit grower as seen in its Earnings Stability factor of 11 out of 99 possible – with a lower number being better.
Check Out The IBD Stock Of The Day
Analysts See Biotech's Profits Surging 471%
TG Therapeutics is in a stage-three consolidation pattern with a 46.48 buy point. Shares pulled back 2.5% Monday and undercut their 50-day moving average.
The biotech stock has traded mostly sideways since it plunged following its mixed first-quarter earnings report on May 5.
Its relative strength line is trending downward, which is a negative for the stock.
The biopharmaceutical developer turned profitable in 2023, with earnings of 9 cents per share. That increased to 15 cents per share in 2024.
FactSet consensus now shows full-year 2025 profit jumping to 86 cents per share, or 471%, followed by $1.76 per share in 2026.
Its revenue grew 90% in the first quarter, following 146% in the previous quarter. Second-quarter sales are projected to soar 88%, followed by 80%, and then 56%.
The biotech is expected to report its second-quarter earnings around the first week of August.
Management owns 11% of shares, showing conviction in TG Therapeutics stock.
TG Therapeutics has one product approved by the U.S. Food and Drug Administration, Bruiumvi, which is used to treat relapsing forms of multiple sclerosis.
Lastly, the biotech stock holds a 97 Composite Rating.
Follow Kimberley Koenig for more stock market news on X, the platform formerly known as Twitter, @IBD_KKoenig.
